

Special Issue

Hepato-Pancreato-Biliary Surgery in the Era of Immunotherapy

Message from the Guest Editor

Immunotherapy has reshaped oncology by harnessing the immune system to recognize and eliminate cancer cells. In hepatobiliary (HPB) malignancies, where treatment options have traditionally been limited, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 are creating new therapeutic opportunities. Tumor regression achieved with immunotherapy can allow patients with initially unresectable disease to undergo curative resection, a scenario rarely possible with older systemic therapies. Moreover, prolonged survival in patients responding to immunotherapy has introduced new clinical situations. These changes highlight an evolving role for surgery in the era of immunotherapy. Questions now arise regarding patient selection, timing of surgery, perioperative outcomes, and the long-term survival of these novel surgical candidates.

This special issue will bring together studies and expert perspectives to explore how immunotherapy is transforming HPB surgery. By examining indications, surgical outcomes, and emerging challenges, we aim to define the opportunities and future directions of surgery for HPB malignancies in the immunotherapy era.

Guest Editor

Dr. Niv Pencovich

Department of General Surgery and Transplantation, Sheba Medical Center, Gray Faculty of Medical and Gealth Sciences, Tel-Aviv University, Tel-Hashomer, Ramat-Gan 52621, Israel

Deadline for manuscript submissions

closed (15 April 2026)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/252244

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).